Immunwork has developed two long-acting drug candidates, TE-8105 and TE-8214, leveraging its fatty acid bundle platform; both are currently undergoing clinical trials.
In addition, the anti-thrombotic candidate TE-6168, designed using the T-E drug development platform, is in the preclinical CMC manufacturing stage.
These three leading candidates target major diseases, including metabolic and endocrine disorders as well as ischemic stroke.
For detailed information, please refer to the relevant pages on the Immunwork website: TE-8105, TE-8214, and TE-6168.
